Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables - Other: 2019-2024

Historic Receivables - Other for BridgeBio Pharma (BBIO) over the last 4 years, with Sep 2024 value amounting to $478,000.

  • BridgeBio Pharma's Receivables - Other fell 90.75% to $478,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $478,000, marking a year-over-year decrease of 90.75%. This contributed to the annual value of $600,000 for FY2023, which is 96.49% down from last year.
  • Per BridgeBio Pharma's latest filing, its Receivables - Other stood at $478,000 for Q3 2024, which was down 27.58% from $660,000 recorded in Q2 2024.
  • In the past 5 years, BridgeBio Pharma's Receivables - Other registered a high of $235.5 million during Q1 2024, and its lowest value of $462,000 during Q1 2021.
  • In the last 3 years, BridgeBio Pharma's Receivables - Other had a median value of $10.8 million in 2023 and averaged $30.7 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first soared by 5,220.56% in 2022, then tumbled by 96.49% in 2023.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Receivables - Other stood at $8.0 million in 2020, then slumped by 94.23% to $19.7 million in 2021, then declined by 13.52% to $17.1 million in 2022, then crashed by 96.49% to $600,000 in 2023, then crashed by 90.75% to $478,000 in 2024.
  • Its Receivables - Other stands at $478,000 for Q3 2024, versus $660,000 for Q2 2024 and $235.5 million for Q1 2024.